Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal recessive non-syndromic intellectual disability in which the cause of the disease is a mutation in the CC2D1A gene.
Features include always present findings: Delayed speech and language development, Global developmental delay, Short attention span, and Hyperactivity and others; and sometimes findings: Progressive microcephaly. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Delayed speech and language development, Global developmental delay, Incomprehensible speech |
CC2D1A encodes coiled-coil and C2 domain containing 1A (951 aa). Transcription factor that binds specifically to the DRE (dual repressor element) and represses HTR1A gene transcription in neuronal cells.
Intellectual disability, autosomal recessive 3 is associated with mutations in the CC2D1A gene on chromosome 19.
CC2D1A is classified as a druggable target (Transcription Factor category) with score 0.0.
Genetic testing for CC2D1A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for intellectual disability, autosomal recessive 3 has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for intellectual disability, autosomal recessive 3.
91 publications have been identified in PubMed for intellectual disability, autosomal recessive 3. Research spans Case Report / Case Series (43%), Basic Science / Preclinical (25%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 36 | 43% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:59 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Head and neck |
2 |
Progressive microcephaly, Hypomimic face |
Laboratory research
21 |
25% |
Research summaries | 11 | 13% |
Disease patterns and progression | 9 | 11% |
Testing and diagnosis research | 3 | 4% |
New treatment approaches | 2 | 2% |
Clinical study results | 1 | 1% |
Salmaninejad A (2026). [PMID: 41866703](https://pubmed.ncbi.nlm.nih.gov/41866703/). *Mol Genet Genomic Med*. [Review / Meta-Analysis]
Heller AT (2026). [PMID: 41765286](https://pubmed.ncbi.nlm.nih.gov/41765286/). *Mol Cell Proteomics*. [Basic Science / Preclinical]
Hashmi MS (2026). [PMID: 32644502](https://pubmed.ncbi.nlm.nih.gov/32644502/). *Unknown Journal*. [Case Report / Case Series]
Pan X (2026). [PMID: 41764152](https://pubmed.ncbi.nlm.nih.gov/41764152/). *J Mol Med (Berl)*. [Basic Science / Preclinical]
Manti F (2026). [PMID: 41450729](https://pubmed.ncbi.nlm.nih.gov/41450729/). *Neurol Genet*. [Case Report / Case Series]
Javed K (2026). [PMID: 41347281](https://pubmed.ncbi.nlm.nih.gov/41347281/). *Ann Hum Genet*. [Basic Science / Preclinical]
Dudic A (2026). [PMID: 40824224](https://pubmed.ncbi.nlm.nih.gov/40824224/). *J Pediatr Orthop*. [Basic Science / Preclinical]
Urquiza N (2026). [PMID: 41475179](https://pubmed.ncbi.nlm.nih.gov/41475179/). *Mol Genet Metab*. [Case Report / Case Series]
Asghar MA (2026). [PMID: 40897375](https://pubmed.ncbi.nlm.nih.gov/40897375/). *Clin Genet*. [Case Report / Case Series]
Ng AC (2026). [PMID: 40990994](https://pubmed.ncbi.nlm.nih.gov/40990994/). *J Child Neurol*. [Case Report / Case Series]